Literature DB >> 11423536

Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity.

R M Lozano1, M Redondo-Horcajo, M A Jimenez, L Zilberberg, P Cuevas, A Bikfalvi, M Rico, G Giménez-Gallego.   

Abstract

Platelet factor-4 is a protein belonging to the family of ELR-negative CXC chemokines which binds to fibroblast growth factor and inhibits its mitogenic activity. Platelet factor-4 also inhibits tumor growth by mechanisms involving antiangiogenesis. Antiangiogenic activity in vitro has also been shown for the 24-residue C-terminal fragment of the protein, which decreases the affinity between basic fibroblast growth factor and its cell-surface receptor. In this study, the preferential conformation of this fragment in solution has been determined and has been found to be composed of two helical subdomains. In addition, we show that the fragment forms a specific 1:1 complex with acidic and basic fibroblast growth factors and that both subdomains are probably required for inhibition of fibroblast growth factor-driven mitogenesis. Finally, we show that the binding of the fragment alters the structure of the fibroblast growth factors, although some of such alterations do not seem related with the inhibition of mitogenic activity. Since this fragment has recently been shown to inhibit fibroblast growth factor-induced angiogenesis in vivo when injected intraperitoneally, these results are relevant for developing new antiangiogenic treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423536     DOI: 10.1074/jbc.M101565200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  The Role of Chemokines in Fibrotic Wound Healing.

Authors:  Jie Ding; Edward E Tredget
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

2.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

Review 3.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

Review 4.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

5.  Dimerization capacities of FGF2 purified with or without heparin-affinity chromatography.

Authors:  Natalia Platonova; Géraldine Miquel; Liang-Yuan Chiu; Said Taouji; Elisabetta Moroni; Giorgio Colombo; Eric Chevet; Shih-Che Sue; Andreas Bikfalvi
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 6.  Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.

Authors:  Asbiel Hasbum; Jaqueline Quintanilla; Juan A Amieva Jr; May-Hui Ding; Arkene Levy; Sue Anne Chew
Journal:  Future Med Chem       Date:  2021-01-05       Impact factor: 3.808

7.  The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis.

Authors:  Sallouha Aidoudi; Kinga Bujakowska; Nelly Kieffer; Andreas Bikfalvi
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.